Unknown

Dataset Information

Investigational protease inhibitors as antiretroviral therapies.


ABSTRACT:

Introduction

Highly Active Antiretroviral Therapy (HAART) has tremendously improved the life expectancy of the HIV-infected population over the past three decades. Protease inhibitors have been one of the major classes of drugs in HAART regimens that are effective in treating HIV. However, the emergence of resistance and cross-resistance against protease inhibitors encourages researchers to develop new PIs with broad-spectrum activity, as well as novel means of enhancing the efficacy of existing PIs.

Areas covered

In this article we discuss recent advances in HIV protease inhibitor (PI) development, focusing on both investigational and experimental agents. We also include a section on pharmacokinetic booster drugs for improved bioavailability of protease inhibitors. Further,

SUBMITTER: Midde NM 

PROVIDER: S-EPMC5228633 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature